6 recruiting, 4 completed, 2 unknown, 1 not yet recruiting. 7 Phase 2, 6 Phase 1, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 2, Recruiting 2, Unknown 2, Not yet recruiting 1 |
| Phase 1 | 6 | Recruiting 4, Completed 1, Unknown 1 |
| Not applicable | 2 | Completed 1, Recruiting 1 |
Follow Neuroendocrine Cancer: new trials by email Literature Review of Neuroendocrine Cancer trials Research Report on Neuroendocrine Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Armored CAR T Cells in People With Cancer DLL3-SAVVYZ-IL18 CAR T cell - Neuroendocrine Cancer, Small Cell Lung Cancer | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 16 | 2026-08-28 | 2026-10-22 |
| TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors TLN-499, Venetoclax - Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer | Phase 1 | Recruiting | Treeline Biosciences, Inc. | 120 | 2026-08-05 | 2026-10-01 |
| AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer AK112, Irinotecan, Cisplatin - Neuroendocrine Cancer | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 56 | 2026-08-01 | 2026-07-17 |
| DLL3-Targeted PET/CT in Neuroendocrine Carcinoma Diagnostic Test: conventional imaging (CT, MRI or 18F-FDG PET/CT), DLL3-targeted PET/CT - DLL3-expressing Tumors, PET / CT | Not applicable | Recruiting | The First Affiliated Hospital of Xiamen University | 80 | 2026-03-10 | 2026-09-25 |
| Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors BL-M14D1 - Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer | Phase 1 | Recruiting | SystImmune Inc. | 120 | 2025-04-28 | 2026-10-28 |
| Ivonescimab in the Treatment of Multiple Advanced Tumors Ivocizumab - Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma | Phase 2 | Recruiting | Fudan University | 400 | 2024-11-20 | 2025-08-24 |
| Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer ZG006 - Small Cell Lung Cancer, Neuroendocrine Cancer | Phase 1 / Phase 2 | Recruiting | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 265 | 2024-09-02 | 2026-10-19 |
| Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors Pembrolizumab, Lenvatinib - Neuroendocrine Tumors, Neuroendocrine Carcinoma | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 20 | 2017-12-15 | 2025-12-22 |
| Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers Carfilzomib - Neuroendocrine Cancer | Phase 2 | Completed | SCRI Development Innovations, LLC | 62 | 2015-07-15 | 2023-12-05 |
| 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography. - Neuroendocrine, Neuroendocrine Tumor | Phase 1 / Phase 2 | Unknown | Ochsner Health System | 250 | 2014-03-01 | 2014-01-17 |
| Clinical Trial of the Impact of Treatment Consultation Recordings on Cancer Patient Outcomes Consultation Recording - Brain Tumor, Neuroendocrine Cancer | Not applicable | Completed | University of Manitoba | 140 | 2013-06-01 | 2018-02-20 |
| Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. PSMA/PRAME - Ovarian, Melanoma | Phase 1 | Completed | Mannkind Corporation | 12 | 2007-02-01 | 2010-08-03 |
| Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors thermochemotherapy, Cisplatin, Gemcitabine, Interferon-a - Neuroendocrine Cancer, Small Cell Lung Cancer | Phase 2 | Unknown | The University of Texas Health Science Center, Houston | 36 | 2002-07-01 | 2011-03-03 |
Carcinoma, Neuroendocrine (13) · Small Cell Lung Carcinoma (5) · Carcinoid Tumor (2) · Neuroendocrine Tumors (2) · Sarcoma (2) · Stomach Neoplasms (2) · Adenoma, Islet Cell (1) · Angiomyolipoma (1) · Anus Neoplasms (1) · Apudoma (1) · Biliary Tract Neoplasms (1) · Bone Neoplasms (1) · Brain Neoplasms (1) · Breast Neoplasms (1) · Carcinoma (1)
Adenocarcinoma (13) · Neoplasms (13) · Neoplasms by Histologic Type (13) · Neoplasms, Germ Cell and Embryonal (13) · Neoplasms, Glandular and Epithelial (13) · Neoplasms, Nerve Tissue (13) · Neuroectodermal Tumors (13) · Carcinoma (12) · Neuroendocrine Tumors (11) · Neoplasms by Site (8) · Bronchial Neoplasms (5) · Carcinoma, Bronchogenic (5) · Lung Diseases (5) · Lung Neoplasms (5) · Respiratory Tract Diseases (5)
Cisplatin (2) · Gemcitabine (1) · Interferon-alpha (1) · Irinotecan (1) · Magnetic Resonance Imaging (1) · carfilzomib (1) · lenvatinib (1) · pembrolizumab (1) · venetoclax (1)
Fudan University (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Mannkind Corporation (1) · Memorial Sloan Kettering Cancer Center (1) · Ochsner Health System (1) · SCRI Development Innovations, LLC (1) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (1) · SystImmune Inc. (1) · The First Affiliated Hospital of Xiamen University (1) · The University of Texas Health Science Center, Houston (1) · Tianjin Medical University Cancer Institute and Hospital (1) · Treeline Biosciences, Inc. (1) · University of Manitoba (1)
United States (7) · China (4) · Australia (1) · Canada (1) · Georgia (1) · Ukraine (1)
Adam Schoenfeld, MD (1) · David Spigel, M.D. (1) · Hongxia Wang, Doctor (1) · Jason Wu (1) · Joan M Bull, M.D. (1) · Jonathan Strosberg, M.D. (1) · Junliang Cai (1) · Padma Yerramilli-Rao, MB BS, PhD (1) · Thomas F Hack, PhD (1)
R01CA303470 (1)